Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress.

[1]  B. Hendriks,et al.  Population pharmacokinetics of ATR inhibitor berzosertib in phase I studies for different cancer types , 2020, Cancer Chemotherapy and Pharmacology.

[2]  P. Meltzer,et al.  SCLC-CellMiner: A Resource for Small Cell Lung Cancer Cell Line Genomics and Pharmacology Based on Genomic Signatures , 2020, Cell reports.

[3]  S. Peters,et al.  Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. , 2020, The Lancet. Oncology.

[4]  D. Pe’er,et al.  Lineage plasticity in cancer: a shared pathway of therapeutic resistance , 2020, Nature Reviews Clinical Oncology.

[5]  Y. Pommier,et al.  BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers , 2020, Science Translational Medicine.

[6]  T. Graeber,et al.  A genetically defined disease model reveals that urothelial cells can initiate divergent bladder cancer phenotypes , 2019, Proceedings of the National Academy of Sciences.

[7]  Damien Y. Duveau,et al.  Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening , 2019, Science Translational Medicine.

[8]  Aurélie A G Gabriel,et al.  Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids , 2019, Nature Communications.

[9]  M. Lawrence,et al.  Combination Olaparib and Temozolomide in Relapsed Small Cell Lung Cancer. , 2019, Cancer discovery.

[10]  T. Graeber,et al.  Pan-cancer Convergence to a Small-Cell Neuroendocrine Phenotype that Shares Susceptibilities with Hematological Malignancies. , 2019, Cancer cell.

[11]  C. Rudin,et al.  Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data , 2019, Nature Reviews Cancer.

[12]  Paul Pinsky,et al.  Characteristics and Outcomes of Small Cell Lung Cancer Detected by CT Screening , 2018, Chest.

[13]  C. Sander,et al.  CellMinerCDB for Integrative Cross-Database Genomics and Pharmacogenomics Analyses of Cancer Cell Lines , 2018, iScience.

[14]  A. Mansfield,et al.  First‐Line Atezolizumab plus Chemotherapy in Extensive‐Stage Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[15]  Alex H. Wagner,et al.  Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer , 2018, Nature Communications.

[16]  C. Rudin,et al.  Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Y. Pommier,et al.  SLFN11 Blocks Stressed Replication Forks Independently of ATR. , 2018, Molecular cell.

[18]  J. Minna,et al.  Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes. , 2018, Translational lung cancer research.

[19]  S. Steinberg,et al.  Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  N. Socci,et al.  Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis , 2017, Clinical Cancer Research.

[21]  S. Jackson,et al.  ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response. , 2017, Molecular cell.

[22]  S. Ramaswamy,et al.  ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells , 2017, Genes & development.

[23]  M. Rubin,et al.  SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer , 2017, Science.

[24]  Samuel E. Jones,et al.  ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A , 2016, Nature Communications.

[25]  Panagiotis Kotsantis,et al.  Increased global transcription activity as a mechanism of replication stress in cancer , 2016, Nature Communications.

[26]  Y. Pommier,et al.  Roles of eukaryotic topoisomerases in transcription, replication and genomic stability , 2016, Nature Reviews Molecular Cell Biology.

[27]  J. Minna,et al.  ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs. , 2016, Cell reports.

[28]  Xingming Deng,et al.  Targeting DNA Replication Stress for Cancer Therapy , 2016, Genes.

[29]  Y. Pommier,et al.  Small cell lung cancer: Time to revisit DNA-damaging chemotherapy , 2016, Science Translational Medicine.

[30]  Gennady Korotkevich,et al.  Fast gene set enrichment analysis , 2016, bioRxiv.

[31]  V. Seshan,et al.  FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing , 2016, Nucleic acids research.

[32]  R. D. de Bruin,et al.  Sustained E2F-Dependent Transcription Is a Key Mechanism to Prevent Replication-Stress-Induced DNA Damage , 2016, Cell reports.

[33]  P. Pinto,et al.  Lack of Impact of Robotic Assisted Laparoscopic Radical Prostatectomy on Intraoperative Levels of Prostate Cancer Circulating Tumor Cells. , 2016, The Journal of urology.

[34]  Hongbing Shen,et al.  Genomic Landscape Survey Identifies SRSF1 as a Key Oncodriver in Small Cell Lung Cancer , 2016, PLoS genetics.

[35]  Matteo Benelli,et al.  Divergent clonal evolution of castration resistant neuroendocrine prostate cancer , 2016, Nature Medicine.

[36]  N. Horita,et al.  Topotecan for Relapsed Small-cell Lung Cancer: Systematic Review and Meta-Analysis of 1347 Patients , 2015, Scientific Reports.

[37]  A. Berns,et al.  Origins, genetic landscape, and emerging therapies of small cell lung cancer , 2015, Genes & development.

[38]  H. Beltran,et al.  The spectrum of neuroendocrine tumors: histologic classification, unique features and areas of overlap. , 2015, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[39]  A. Eastman,et al.  Will targeting Chk1 have a role in the future of cancer therapy? , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  P. Meltzer,et al.  Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. , 2015, The Lancet. Oncology.

[41]  Y. Pommier,et al.  ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses. , 2014, Cancer research.

[42]  I. Drozdov,et al.  Gene network-based analysis identifies two potential subtypes of small intestinal neuroendocrine tumors , 2014, BMC Genomics.

[43]  J. Diffley,et al.  DNA Replication and Oncogene-Induced Replicative Stress , 2014, Current Biology.

[44]  David Hsu,et al.  OpenComet: An automated tool for comet assay image analysis , 2014, Redox biology.

[45]  K. Cimprich,et al.  Causes and consequences of replication stress , 2013, Nature Cell Biology.

[46]  L. Zou,et al.  Two distinct modes of ATR activation orchestrated by Rad17 and Nbs1. , 2013, Cell reports.

[47]  Takanori Fujita,et al.  PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small cell lung cancer , 2013, Scientific Reports.

[48]  Justin Guinney,et al.  GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.

[49]  Robert Gentleman,et al.  Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer , 2012, Nature Genetics.

[50]  Martin A. M. Reijns,et al.  Enzymatic Removal of Ribonucleotides from DNA Is Essential for Mammalian Genome Integrity and Development , 2012, Cell.

[51]  M. Barbacid,et al.  Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors , 2011, Nature Structural &Molecular Biology.

[52]  James R Bischoff,et al.  A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations , 2011, Nature Structural &Molecular Biology.

[53]  Helga Thorvaldsdóttir,et al.  Molecular signatures database (MSigDB) 3.0 , 2011, Bioinform..

[54]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[55]  H. Hakonarson,et al.  ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.

[56]  Richard Durbin,et al.  Fast and accurate long-read alignment with Burrows–Wheeler transform , 2010, Bioinform..

[57]  Davis J. McCarthy,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[58]  J. D. Vos,et al.  Topoisomerase I suppresses genomic instability by preventing interference between replication and transcription , 2009, Nature Cell Biology.

[59]  Jiri Bartek,et al.  An Oncogene-Induced DNA Damage Model for Cancer Development , 2008, Science.

[60]  Y. Pommier,et al.  The Intra-S-Phase Checkpoint Affects both DNA Replication Initiation and Elongation: Single-Cell and -DNA Fiber Analyses , 2007, Molecular and Cellular Biology.

[61]  T. Ciuleanu,et al.  Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  Dimitris Kletsas,et al.  Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints , 2006, Nature.

[63]  Wolf-Dietrich Heyer,et al.  Rad54: the Swiss Army knife of homologous recombination? , 2006, Nucleic acids research.

[64]  N. Hanna,et al.  Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  T. Ørntoft,et al.  DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis , 2005, Nature.

[66]  Dimitris Kletsas,et al.  Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions , 2005, Nature.

[67]  A. Kumagai,et al.  Claspin, a novel protein required for the activation of Chk1 during a DNA replication checkpoint response in Xenopus egg extracts. , 2000, Molecular cell.

[68]  K. Kohn,et al.  Replication‐mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA‐dependent protein kinase and dissociates RPA:DNA‐PK complexes , 1999, The EMBO journal.

[69]  J. Carmichael,et al.  Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  M. Prichard,et al.  A three-dimensional model to analyze drug-drug interactions. , 1990, Antiviral research.

[71]  J. Minna,et al.  Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties. , 1985, Cancer research.

[72]  J. Bishop,et al.  INSM1 is a Sensitive and Specific Marker of Neuroendocrine Differentiation in Head and Neck Tumors , 2018, The American journal of surgical pathology.

[73]  Yilun Sun,et al.  Detection of Topoisomerase Covalent Complexes in Eukaryotic Cells. , 2018, Methods in molecular biology.

[74]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.